Immunotech Biopharm Ltd. announce that the Company has completed the first patient enrolment for its Phase II clinical trial for CAR-T-19 injection ("CAR-T-19 Injection") in the PRC, which marked a key milestone of the Group's development in its product pipeline. CAR-T-19 Injection is indicated for the treatment of pediatric and young adult patients up to and including the age of 25 with relapsed/refractory B cell acute lymphoblastic leukaemia ("B-ALL"). Based on the progress of clinical trial for CAR-T-19 Injection, it is expected that the target patient enrolment would complete by the end of 2025 and the preliminary analysis and results would be published in the first half of 2026.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.39 HKD | +3.67% | -0.29% | -32.20% |
03-29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
03-28 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-32.20% | 223M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- 6978 Stock
- News Immunotech Biopharm Ltd
- Immunotech Biopharm Ltd Announces First Patient Enrolled in the Phase II Clinical Trialfor Car-T-19 Injection